Study to Test a Marketed Product in the Treatment of Migraine-associated Nausea

Organon

Status and phase: Completed; Phase 3

Conditions: Migraine

Treatments: Drug: Comparator: Placebo; Drug: Comparator: Rizatriptan

Study type: Interventional

Funder types: Industry

Identifiers

NCT00250458

0462-074

2005_081

Details and patient eligibility

About

Study to test the effectiveness of a marketed drug in the treatment of migraine-associated nausea.

Enrollment: 346 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 6-month history of migraine, moderate to severe migraine attacks with nausea, 1-6 migraine attacks per month

Exclusion criteria

• Heart disease, high blood pressure

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

346 participants in 2 patient groups, including a placebo group

1

Experimental group

Description:

Rizatriptan (MK0462)10 mg orally disintegrating tablet/oral lyophilisate

Treatment:

Drug: Comparator: Rizatriptan

2

Placebo Comparator group

Description:

matching placebo

Treatment:

Drug: Comparator: Placebo